Dimensional Fund Advisors LP Buys 73,062 Shares of Aura Biosciences, Inc. (NASDAQ:AURA)

Dimensional Fund Advisors LP boosted its position in shares of Aura Biosciences, Inc. (NASDAQ:AURA - Free Report) by 25.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 365,824 shares of the company's stock after buying an additional 73,062 shares during the period. Dimensional Fund Advisors LP owned approximately 0.73% of Aura Biosciences worth $3,007,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of AURA. Barclays PLC boosted its stake in shares of Aura Biosciences by 19.2% in the 4th quarter. Barclays PLC now owns 72,725 shares of the company's stock valued at $598,000 after purchasing an additional 11,715 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Aura Biosciences by 489.4% in the 4th quarter. Renaissance Technologies LLC now owns 83,700 shares of the company's stock valued at $688,000 after purchasing an additional 69,500 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Aura Biosciences by 27.3% in the 4th quarter. Wells Fargo & Company MN now owns 27,623 shares of the company's stock valued at $227,000 after purchasing an additional 5,930 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Aura Biosciences by 0.4% in the 4th quarter. Geode Capital Management LLC now owns 1,012,799 shares of the company's stock valued at $8,327,000 after purchasing an additional 3,972 shares in the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of Aura Biosciences by 3.2% in the 4th quarter. Franklin Resources Inc. now owns 1,723,063 shares of the company's stock valued at $14,164,000 after purchasing an additional 54,103 shares in the last quarter. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

AURA has been the topic of a number of research analyst reports. HC Wainwright set a $25.00 price target on shares of Aura Biosciences in a research note on Tuesday, March 25th. Citigroup reiterated an "outperform" rating on shares of Aura Biosciences in a report on Wednesday, March 26th. Lifesci Capital upgraded shares of Aura Biosciences to a "strong-buy" rating in a report on Friday, January 31st. Finally, JMP Securities set a $19.00 price objective on shares of Aura Biosciences in a report on Wednesday, March 26th. Six investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $22.75.

Aura Biosciences Stock Up 14.9%

Aura Biosciences stock traded up $0.77 during mid-day trading on Friday, hitting $5.95. 746,587 shares of the stock were exchanged, compared to its average volume of 209,454. Aura Biosciences, Inc. has a 12 month low of $4.35 and a 12 month high of $12.38. The firm's fifty day simple moving average is $5.91 and its two-hundred day simple moving average is $7.56. The stock has a market capitalization of $298.84 million, a price-to-earnings ratio of -3.44 and a beta of 0.43.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.08). As a group, analysts forecast that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Aura Biosciences news, insider Conor Kilroy sold 7,162 shares of the firm's stock in a transaction that occurred on Wednesday, April 16th. The shares were sold at an average price of $5.49, for a total transaction of $39,319.38. Following the completion of the transaction, the insider now owns 179,313 shares in the company, valued at approximately $984,428.37. This trade represents a 3.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last 90 days, insiders sold 14,148 shares of company stock worth $91,434. 5.40% of the stock is currently owned by insiders.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.